Cure Alzheimer's Fund's Dr. Rudy Tanzi discusses the latest Alzheimer's research on flavonoids and new drugs being developed to prevent and slow the disease on World Health News Today.

 Please click here to view the first segment of the interview

Two new Alzheimer's drugs, Flurizan (Myriad) and Bapineuzumab (Wyeth/Elan), failed clinical trials. Cure Alzheimer's Fund's Dr. Rudy Tanzi offers some prespective on these drugs.

Read the CNN Money Myriad (Flurizan) press release here

Read the ABC News report on Flurizan

Read the Wyeth/Elan bapineuzumab press release here

Clinical Trial Update
By Dr. Rudolph Tanzi, Massachusetts General Hospital

The results of two clinical trials for Alzheimer’s disease (AD) based on the “amyloid (Αβ) hypothesis of AD” were recently released -- flurizan (Myriad) and bapineuzumab (Wyeth/Elan).  These therapies are aimed at slowing disease progression by curbing the accumulation of Αβ in the brain.

Cure Alzheimer's Fund's Dr. Rudy Tanzi will appear on PBS's NOVA scienceNOW on Wednesday, July 2, to discuss genetic testing and it's impact on Alzheimer's and other hereditary diseases.

Click here for more details about the show

June 8, 2008 Los Angeles Times opinion piece by author and Middlebury scholar Sue Halpern says the years of Alzheimer's research may be paying dividends with new treatments that will stave off the disease.

Halpern quotes Cure Alzheimer's Fund Dr. Rudy Tanzi explaining the disease: "The main place where a-beta 42 does its work is in the synapse. So every minute of the day, an Alzheimer patient is producing a-beta 42, for one reason or another, and it's accumulating in the brain ... it's accumulating ... in the synapse. Way, way before the plaques form, you get tiny little aggregates of a-beta 42. The peptides stick together and they get into the synapse and they disrupt the most basic synaptic function for learning and memory."

Click here to view the op-ed